Research programme: RNAi-based hepatitis C virus therapeutics - Tacere Therapeutics

Drug Profile

Research programme: RNAi-based hepatitis C virus therapeutics - Tacere Therapeutics

Alternative Names: OBP-701; RNAi HCV therapeutics - Tacere Therapeutics/Oncolys BioPharma; RNAi HCV therapeutics - Tacere Therapeutics/Pfizer; TT-033; TT-033i

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Benitec Ltd
  • Developer Tacere Therapeutics
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (IV, Injection)
  • 30 Oct 2012 Tacere Therapeutics has been acquired by Benitec Biopharma
  • 11 Oct 2012 Pfizer returns rights to the HCV programme to Tacere
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top